EUCTR2005-005921-73-IT进行中（未招募）不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab 0.3 mg in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - ND
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients 50 years of age or greater. Diagnosis of active primary or recurrent CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component. The total area of CNV encompassed within the lesion must be 50 of hte total lesion area
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous treatment with intravitreally or intravenously administered Avasatin. Laser photocoagulation, treatment with intravitreal steroids, verteporfin photodynamic therapy or pegaptanib sodium in the study eye within 30 days preceding day 1. Prior treatment in the study eye whit external-beam radiation terapy, vitreoctomy, or transpupillary thermotherapy.
研究者
相似试验
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIMale and female patients =50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)EUCTR2005-005921-73-HUovartis Pharma Service AG500
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 and/or 0.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIMale and female patients =50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)EUCTR2005-005921-73-DEovartis Pharma Service AG500
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIEUCTR2005-005921-73-PTovartis Pharma Service AG500
进行中（未招募）
1 期
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIMale and female patients =50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)EUCTR2005-005921-73-NLovartis Pharma Service AG
进行中（未招募）
1 期
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIMale and female patients =50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)EUCTR2005-005921-73-GBovartis Pharma Services AG